Integration of EGFR Inhibitors With Radiochemotherapy

Nature Reviews Cancer- United Kingdom

doi 10.1038/nrc2030

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Reverse of EGFR Inhibitors Resistance by Co-Delivering EGFR and Integrin Αvβ3 Inhibitors With Nanoparticles in Non-Small Cell Lung Cancer

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2019English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2013English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology
2014English

EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

OncoImmunology
OncologyAllergyImmunology
2012English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

Accelerated Hyperfractionated Radiochemotherapy With Temozolomide Is Equivalent to Normofractionated Radiochemotherapy in a Retrospective Analysis of Patients With Glioblastoma

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

QSAR Based Model for Discriminating EGFR Inhibitors and Non-Inhibitors Using Random Forest

Biology Direct
EvolutionEcologyGeneticsMolecular BiologyBiochemistryApplied MathematicsSystematicsSimulationImmunologyBehaviorBiological SciencesAgriculturalModeling
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy